Advertisement

Diagnostic Tests for the Evaluation of Pituitary Tumors

  • Ivor M. D. Jackson

Abstract

Following the description of the technique of radioimmunoassay1 (RIA) and its application to the measurement of pituitary hormones, disorders of pituitary function could be diagnosed much more readily than before. The subsequent development of a specific RIA for human prolactin2 (PRL) has revolutionized our means of diagnosing pituitary tumors, for it has become clear that 50–80% of tumors that previously were categorized as inactive chromophobe adenomas actively secrete PRL.3

Keywords

Growth Honnone Pituitary Adenoma Pituitary Tumor Pituitary Hormone Thyrotropin Release Hormone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    R.S. Yalow and S.A. Berson, Immunoassay of endogenous plasma insulin in man, J. Clin. invest. 39:1157–1175, 1960.PubMedCrossRefGoogle Scholar
  2. 2.
    Hwang, H. Guyda, and H. Friesen, A radioimmunoassay for human prolactin, Proc. Natl. Acad. Sci. U.S.A. 68:1902–1906, 1971.PubMedCrossRefGoogle Scholar
  3. 3.
    A.G. Frantz, Prolactin, N. Engl. J. Med. 298:201–207, 1978.PubMedCrossRefGoogle Scholar
  4. 4.
    R. Burgus, T. Dunn, D. Desiderio, and G. Guillemin, Structure moleculaire du facteur hypothalamique hypophysiotrope TRF d’origine ovine: Mise en evidence par spectromètre de masse de la sequence PCA-HIS-PRO-NH2, C. R. Acad. Sci. (Paris) 269:1870–1873, 1969.Google Scholar
  5. 5.
    J. Bøler, F. Enzmann, K. Folkers, C.Y. Bowers, and A.V. Schally, The identity off chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidylproline-amide, Biochem. Biophys. Res. Commun. 37:705–710, 1969.PubMedCrossRefGoogle Scholar
  6. 6.
    A.V. Schally, A. Arimura, A.J. Kastin, H. Matsuo, Y. Baba, T.W. Redding, R.M.G. Nair, L. Debeljuk, and W.F. White, Gonadotropin-releasing hormone: One polypeptide regulates secretion of luteinizing and follicle stimulating hormones, Science 173:1036–1038, 1971.PubMedCrossRefGoogle Scholar
  7. 7.
    P. Brazeau, W. Vale, R. Burgus, N. Ling, M. Butcher, J. Rivier, and R. Guillemin, Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone, Science 179:77–79, 1973.PubMedCrossRefGoogle Scholar
  8. 8.
    I.M.D. Jackson, Extrahypothalamic and phylogenetic distribution of hypothalamic peptides in: The Hypothalamus (S. Reichlin, R.J. Baldessarini, and J.B. Martin, eds.), pp. 217–231, Raven Press, New York, 1978.Google Scholar
  9. 9.
    G.W. Harris, Neural control of the pituitary gland, Physiol. Rev. 28:139–179, 1948.PubMedGoogle Scholar
  10. 10.
    R.J. Wurtman, Brain monomamines and endocrine function, Neurosci. Bes. Prog. Bull. 9:172–297, 1971.Google Scholar
  11. 11.
    M.T. Rabkin and A.G. Frantz, Hypopituitarism: A study of growth hormone and other endocrine function, Ann. Intern. Med. 64:1197–1966.Google Scholar
  12. 12.
    J.S. Jenkins, C.J. Gilbert, and V. Ang, Hypothalamic-pituitary function in patients with craniopharyngiomas, J. Clin. Endocrinol. Metab. 43:394–399, 1976.PubMedCrossRefGoogle Scholar
  13. 13.
    R.L. Eddy, P.F. Gilliland, J.D. Ibarra, et al., Human growth hormone release, Am. J. Med. 56:179–185, 1974.PubMedCrossRefGoogle Scholar
  14. 14.
    A.G. Frantz and M.T. Rabkin, Effects of estrogen and sex difference on secretion of human growth hormone, J. Clin. Endocrinol. Metab. 25:1470–1480, 1965.PubMedCrossRefGoogle Scholar
  15. 15.
    W.B. Mendelson, L.S. Jacobs, J.D. Reichman, et al., Methysergide suppression of sleep-related prolactin secretion and enhancement of sleep related growth hormone secretion, J. Clin. Invest. 56:690–697, 1975.PubMedCrossRefGoogle Scholar
  16. 16.
    J. Landon, F.C. Greenwood, T.C.B. Stamp, and V. Wynn, The plasma sugar, free fatty acid, Cortisol and growth hormone response to insulin and the comparison of this procedure with other tests of pituitary and adrenal function, J. Clin. Invest. 45:437, 1966.PubMedCrossRefGoogle Scholar
  17. 17.
    P.E. Cryer and W.H. Daughaday, Adrenergic modulation of growth hormone secretion in acromegaly: Suppression during phentolamine and phentolamine—isoproterenol administration, J. Clin. Endocrinol. Metab 39:658–663, 1974.PubMedCrossRefGoogle Scholar
  18. 18.
    M.L. Mitchell, M.J. Byrne, Y. Sanchez, and C.T. Sawin, Detection of growth hormone deficiency: The glucagon stimulation test, N. Engl. J. Med. 282:539–541, 1970.PubMedCrossRefGoogle Scholar
  19. 19.
    R.E. Johnsonbaugh, D.E. Bybee, and L.P. George, Exercise tolerance test: Single-sample screening technique to rule out growth-hormone deficiency, J. Am. Med. Assoc. 240:664–666, 1978.CrossRefGoogle Scholar
  20. 20.
    W.H. Daughaday, P.E. Cryer, and L.S. Jacobs, The role of the hypothalamus in the pathogensis of pituitary tumors in: Diagnosis and Treatment of Pituitary Tumors (P.O. Kohler and G.T. Ross, eds.), pp. 26–34, Excerpta Medica, Amsterdam, 1973.Google Scholar
  21. 21.
    F. Cammani, G.B. Picotti, F. Massara, C.M. Molinatti, P. Mategazza, and E.E. Müller, Carbidopa inhibits the growth hormone and prolactin-suppression effect of L-dopa in acromegalic patients, J. Clin. Endocrinol. Metab. 47:647–651, 1978.CrossRefGoogle Scholar
  22. 22.
    A. Gomez-Pan, W.M.G. Tunbridge, A. Duns, R. Hall, C.M. Besser, D.H. Coy, A.V. Schally, and A.J. Kastin, Hypothalamic hormone interaction in acromegaly, Clin. Endocrinol. 4:455–460, 1975.CrossRefGoogle Scholar
  23. 23.
    A. Liuzzi, P.G. Chiodini, L. Botalla, F. Silvestrini, and E.E. Müller, Growth hormone releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: Homogeneity in the two responses, J. Clin. Endocrinol. Metab. 39:871–876, 1974.PubMedCrossRefGoogle Scholar
  24. 24.
    N.A. Samaan, M.E. Leavens, and R.H. Jesse, Serum growth hormone and prolactin response to thyrotropin-releasing hormone in patients with acromegaly before and after surgery, J. Clin. Endocrinol. Metab. 38:957–963, 1974.PubMedCrossRefGoogle Scholar
  25. 25.
    K.M. Hoyte and J.B. Martin, Recovery from paradoxical growth hormone responses in acromegaly after trans-sphenoidal selective adenomaectomy, J. Clin. Endocrinol. Metab. 41:656–659, 1975.PubMedCrossRefGoogle Scholar
  26. 26.
    G. Faglia, A. Paracchi, C. Ferrari, and P. Beck-Peccoz, Evaluation of the results of transsphenoidal surgery in acromegaly by assessment of the growth hormone response to thyrotrophin-releasing hormone, Clin. Endocrinol. 8:373–380, 1978.Google Scholar
  27. 27.
    H.E. Carlson, J.R. Sowers, and R.W. Rand, Lack of effect of thyroid hormones on the growth hormone response to thyrotropin-releasing hormone acromegaly, Metabolism 26:801–805, 1977.PubMedCrossRefGoogle Scholar
  28. 28.
    L. Belforte, F. Camanni, P.G. Chiodini, A. Liuzzi, F. Massara, G.M. Molinatti, E.E. Müller, and F. Silvestrini, Long term treatment with 2-Br-α-ergocryptine in acromegaly, Acta Endocrinol. 85:235–248, 1977.PubMedGoogle Scholar
  29. 29.
    M. Ishibashi, T. Yamaji, and K. Kosaka, Induction of growth hormone and prolactin secretion by luteinizing hormone-releasing hormone and its blockade by bromergocryptine in acromegalic patients, J. Clin. Endocrinol. Metab. 47:418–421, 1978.PubMedCrossRefGoogle Scholar
  30. 30.
    M. Ishibashi and T. Yamaji, Effect of thyrotropin-releasing hormone and bromocriptine on growth hormone and prolactin secretion in perfused pituitary adenoma tissues of acromegaly, J. Clin. Endocrinol. Metab. 47:1251–1256, 1978.PubMedCrossRefGoogle Scholar
  31. 31.
    P.C. Eskildsen, P.A. Svendsen, L. Vang, and J. Nerup, Long-term treatment of acromegaly with bromocriptine, Acta Endocrinol. 87:687–700, 1978.PubMedGoogle Scholar
  32. 32.
    P.J. Snyder, L.S. Jacobs, M.M. Rabello, et al., Diagnostic value of thyrotropin-releasing hormone in pituitary and hypothalamic diseases, Ann. Intern. Med. 81:751–757, 1974.PubMedGoogle Scholar
  33. 33.
    A.E. Boyd, S. Reichlin, and R.N. Turksoy, Galactorrhea-amenorrhea syndrome diagnosis and therapy, Ann. Intern. Med. 87:165–175, 1977.PubMedGoogle Scholar
  34. 34.
    D.L. Kleinberg, G.L. Noel, and A.G. Frantz, Galactorrhea: A study of 235 cases, including 48 with pituitary tumors, N. Engl. J. Med. 296:589–600, 1977.PubMedCrossRefGoogle Scholar
  35. 35.
    S.A. Fine and L.A. Frohman, Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors, J. Clin. Invest. 61:973–980, 1978.PubMedCrossRefGoogle Scholar
  36. 36.
    C.M. Besser and C.R.W. Edwards, Cushing’s syndrome, Clin. Endocrinol. Metab. 1:451–490, 1972.Google Scholar
  37. 37.
    I.M.D. Jackson and J.I. Mowat, The hypothalamic-pituitary-adrenal axis in obesity and the effect of prolonged fasting on the Cortisol secretion rate, Acta Endocrinol. (Copenhagen) 63:415–422, 1970.Google Scholar
  38. 38.
    J. Lindholm, H. Kehlet, M. Blichert-Toft, B. Dinesen, and J. Riishede, Reliability of the 30 minute ACTH test in assessing hypothalamic-pituitary-adrenal function, J. Clin. Endocrinol. Metab. 47:272–274, 1978.PubMedCrossRefGoogle Scholar
  39. 39.
    C.D. West and L.I. Dolman, Plasma ACTH radioimmunoassays in the diagnosis of pituitary-adrenal function, Ann. N.Y. Acad. Sci. 297:205–219, 1977.PubMedCrossRefGoogle Scholar
  40. 40.
    H.S. Jacobs and J.D. Nabarro, Tests of hypothalamic-pituitary-adrenal function in man, Q. J. Med. 38:475–491, 1969.PubMedGoogle Scholar
  41. 41.
    J.S. Jenkins and W. Else, Pituitary-adrenal function tests in patients with untreated pituitary tumors, Lancet 2:940–943, 1968.PubMedCrossRefGoogle Scholar
  42. 42.
    J.F. Caro, A.W. Meikle, J.H. Check, and S.N. Cohen, “Normal suppression” to dexamethasone in Cushing’s disease: An expression of decreased metabolic clearance for dexamethasone, J. Clin. Endocrinol. Metab. 47:667–670, 1978.PubMedCrossRefGoogle Scholar
  43. 43.
    L.G. Largerquist and F.H. Tyler, Diagnosis and treatment of disorders of the adrenal cortex, Pharmacol. Ther. C 1:259–277, 1976.Google Scholar
  44. 44.
    R.D. Brown, G.R. Van Loon, D.N. Orth, and G.W. Liddle, Cushing’s disease with periodic hormonogenesis: One explanation for paradoxical response to dexamethasone, J. Clin. Endocrinol. Metab. 36:445–451, 1973.PubMedCrossRefGoogle Scholar
  45. 45.
    H.J. Ruder, D.L. Loriaux, and M.B. Lipsett, Severe osteopenia in young adults associated with Cushing’s syndrome due to micronodular adrenal disease, J. Clin. Endocrinol. Metab. 39:1138–1147, 1974.PubMedCrossRefGoogle Scholar
  46. 46.
    D.C. Anderson, P.F. Child, C.H. Sutcliffe, C.H. Buckley, D. Davies, and D. Longson, Cushing’s syndrome, nodular adrenal hyperplasia and virilizing carcinoma, Clin. Endocrinol. 9:1–14, 1978.CrossRefGoogle Scholar
  47. 47.
    J.C. Nelson and D.J. Tindall, A comparison of the adrenal responses to hypoglycemia, metyrapone and ACTH, Am. J. Med. Sci. 275:165–172, 1978.PubMedCrossRefGoogle Scholar
  48. 48.
    M. Luria and D.T. Krieger, Response of plasma ACTH to TRF, vasopressin or hypoglycemia in Cushing’s disease and Nelson’s syndrome, Clin. Res. 24:274A, 1976.Google Scholar
  49. 49.
    D.T. Krieger and E.M. Condon, Cyproheptadine treatment of Nelson’s syndrome: Restoration of plasma ACTH circadian periodicity and reversal of response to TRF, J. Clin. Endocrinol. Metab. 46:349–352, 1978.PubMedCrossRefGoogle Scholar
  50. 50.
    A.L. Kennedy, B. Sheridan, and D.A.D. Montgomery, ACTH and Cortisol response to bromocriptine and results of long term therapy in Cushing’s disease, Acta Endocrinol. 89:461–468, 1978.PubMedGoogle Scholar
  51. 51.
    A.M. Schall, J.S. Brodkey, B. Kaufman, and O.H. Pearson, Pituitary function after removal of pituitary microadenomas in Cushing’s disease, J. Clin. Endocrinol. Metab. 47:410–417, 1978.CrossRefGoogle Scholar
  52. 52.
    H.G. Burger and Y.C. Patel, Thyrotrophin releasing hormone—TSH, Clin. Endocrinol. Metab. 6:83–100, 1977.PubMedCrossRefGoogle Scholar
  53. 53.
    W.E. Cobb, S. Reichlin, and I.M.D. Jackson, The diagnostic value of the TRH test (in prep.), 1980.Google Scholar
  54. 54.
    G. Faglia, C. Ferrari, A. Paracchi, A. Spada, and P. Beck-Peccoz, Triiodothyronine response to thyrotrophin releasing hormone in patients with hypothalamic-pituitary disorders, Clin. Endocrinol. 4:585–590, 1975.CrossRefGoogle Scholar
  55. 55.
    V.B. Peterson, A.M. McGregor, P.E. Belchetz, R.S. Elkeles, and R. Hall, The secretion of thyrotrophin with impaired biological activity in patients with hypothalamic-pituitary disease, Clin. Endocrinol. 8:397–402, 1978.CrossRefGoogle Scholar
  56. 56.
    W.E. Cobb, S. Reichlin, and I.M.D. Jackson, Importance of growth hormone (GH) in regulating the thyrotropin (TSH) response to thyrotropin releasing hormone (TRH) in patients with hypothalamic-pituitary (HP) disease, Endocrinology 103 (Suppl.): T-8, 1978.Google Scholar
  57. 57.
    B.H. Costom, M.M. Grumbach, and S.L. Kaplan, Effect of thyrotropin releasing factor in serum thyroid stimulating hormone: An approach to distinguishing hypothalamic from pituitary forms of idopathic hypopituitary dwarfism, J. Clin. Invest. 50:2219–2225, 1971.PubMedCrossRefGoogle Scholar
  58. 58.
    J.S. Parks, A. Tenore, A.M. Bongiovanni, and R.T. Kirkland, Familial hypopituitarism with large sella turcica, N. Engl. J. Med. 298:698–702, 1978.PubMedCrossRefGoogle Scholar
  59. 59.
    I.M.D. Jackson, Pituitary enlargement resulting from primary thyroid disease, Proc. R. Soc. Med. 63:578, 1970.PubMedGoogle Scholar
  60. 60.
    G. Faglia, P. Beck-Peccoz, C. Ferrari, B. Ambrosi, A. Spada, P. Travaglini, and S. Paracchi, Plasma thyrotropin response to thyrotropin-releasing hormone in patients with pituitary and hypothalamic disorders, J. Clin. Endocrinol. Metab. 37:595–601, 1973.PubMedCrossRefGoogle Scholar
  61. 61.
    R.J. Santen, J.M. Leonard, R.T. Sherins, et al., Short and long term effects of clomiphene citrate on the pituitary-testicular axis, J. Clin. Endocrinol. Metab. 33:970–979, 1971.PubMedCrossRefGoogle Scholar
  62. 62.
    P. Franchimont, J.C. Valcke, and R. Lambotte, Female gonadal dysfunction, Clin. Endocrinol. Metab. 3:533–536, 1974.PubMedCrossRefGoogle Scholar
  63. 63.
    A.M. Coscia, N. Fleischer, P.K. Besch, et al., The effect of synthetic luteinizing hormone-releasing factor on plasma LH levels in pituitary disease, J. Clin. Endocrinol. Metab. 38:83–88, 1974.PubMedCrossRefGoogle Scholar
  64. 64.
    C.H. Mortimer, G.M. Besser, A.S. McNeilly, et al., The LH and FSH releasing hormone test in patients with hypothalamic-pituitary-gonadal dysfunction, Br. Med. J. 4:73–77, 1973.PubMedCrossRefGoogle Scholar
  65. 65.
    C.H. Mortimer, Clinical applications of the gonadotrophin releasing hormone, Clin. Endocrinol. Metab. 6:167–179, 1977.PubMedCrossRefGoogle Scholar
  66. 66.
    T. Hashimoto, K. Miyai, T. Uozumi, S. Mori, M. Watanabe, and Y. Kumahara, Effect of prolonged LH-releasing hormone administration on gonadotropin release in patients with hypothalamic and pituitary tumors, J. Clin. Endocrinol. Metab. 41:712–716, 1975.PubMedCrossRefGoogle Scholar
  67. 67.
    L.L. Schroeder, J.C. Johnson, and M.B. Malarkey, Cerebrospinal fluid prolactin: A reflection of abnormal prolactin secretion in patients with pituitary tumors, J. Clin. Endocrinol. Metab. 43:1255–1260, 1976.PubMedCrossRefGoogle Scholar
  68. 68.
    B. Biller, K. Post, M. Molitch, S. Reichlin, and I. Jackson, CSF pituitary and hypothalamic hormone concentration in patients with prolactinomas, 45th Meeting of the Program of American Association of Neurological Surgeons, New Orleans, Louisiana, Abstract No. 28, 1977.Google Scholar
  69. 69.
    R.M. Jordan, J.W. Kendall, J.L. Search, et al., Cerebrospinal fluid hormone concentration in the evaluation of pituitary tumors, Ann, Intern. Med. 85:49–55, 1976.Google Scholar
  70. 70.
    I.A. Kourides, B.D. Weintraub, S.W. Rosen, et al., Secretion of alpa subunits of glycoprotein hormones by pituitary adenomas, J. Clin. Endocrinol. Metab. 43:97–106, 1976.PubMedCrossRefGoogle Scholar
  71. 71.
    Y. Takahashi, D.M. Kipnis, and W.H. Daughaday, Growth hormone secretion during sleep, J. Clin. Invest. 47:2079–2090, 1968.PubMedCrossRefGoogle Scholar
  72. 72.
    D.C. Parker, L.G. Rossman, and E.F. Vanderlaan, Relation of sleep-entrained human prolactin release to REM-non REM cycles, J. Clin. Endocrinol. Metab. 38:646–651, 1974.PubMedCrossRefGoogle Scholar
  73. 73.
    R.M. Boyar, S. Kapen, J.W. Finkelstein, et al., Hypothalamic-pituitary function in diverse hyperprolactinemic states, J. Clin. Invest. 53:1588–1598, 1974.PubMedCrossRefGoogle Scholar
  74. 74.
    D.T. Krieger and S.M. Glick, Growth hormone and Cortisol responsiveness in Cushing’s syndrome: Relation to a possible central nervous system etiology, Am. J. Med. 52:25–40, 1972.PubMedCrossRefGoogle Scholar
  75. 75.
    P.A. Singer and J.T. Nicoloff, Assessment of thyrotropin-releasing hormone and thyrotropin reserve in man, J. Clin. Invest. 52:1099–1107, 1973.PubMedCrossRefGoogle Scholar
  76. 76.
    L. Bitensky, Cytochemical bioassays of polypeptide hormones, J. Reprod. Fertil. 51:287–294, 1977.PubMedCrossRefGoogle Scholar
  77. 77.
    A.C. Herington, L.S. Jacobs, and W.H. Daughaday, Radioreceptor and radioimmunoassay quantitation of human growth hormone in acromegalic serum: Over estimation by immunoassay and systematic differences between antisera, J. Clin. Endocrinol. Metab. 39:257–268, 1974.PubMedCrossRefGoogle Scholar
  78. 78.
    W.P. Vanderlaan, M.B. Sigel, R.M.P. Singh, E.F. Vanderlaan, and U.T. Lewis, Radioimmunoassay evidence that 2 chain hGH circulates in blood, Program of the 60th Meeting of the Endocrine Society, Miami, Florida, p. 379, 1978 (Abstract No. 609).Google Scholar
  79. 79.
    P.E. Garnier, M.L. Aubert, S.L. Kaplan, and M.M. Grumbach, Heterogeneity of pituitary and plasma prolactin in man: Descreased affinity of “big” prolactin in a radioreceptor assay and evidence for its secretion, J. Clin. Endocrinol. Metab. 47:1273–1281, 1978.PubMedCrossRefGoogle Scholar
  80. 80.
    C.R.W. Edwards, Vasopressin and oxytocin in health and disease, Clin. Endocrinol. Metab. 6:223–259, 1977.PubMedCrossRefGoogle Scholar
  81. 81.
    K.L. Cohen, Metabolic, endocrine and drug-induced interference with pituitary function tests: A review, Metabolism 26:1165–1177, 1977.Google Scholar
  82. 82.
    P. Harsoulis, J.C. Marshall, S.F. Kuku, C.W. Burke, D.R. London, and T.R. Fraser, Combined test for assessment of anterior pituitary function, Br. Med. J. 2:326–329, 1973.CrossRefGoogle Scholar
  83. 83.
    J. Rakoff, G. Vandenberg, T.M. Silver, and S.S.C. Yen, An integrated direct functional test of the adenohypophysis, Am. J. Obstet. Gynecol. 119:358–368, 1974.PubMedGoogle Scholar
  84. 84.
    D.C.L. Savage, P.G. Swift, P.G.B. Johnston, D.J. Goldie, and D. Murphy, Combined test of anterior pituitary function in children, Arch. Dis. Child. 53:301–304, 1978.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1980

Authors and Affiliations

  • Ivor M. D. Jackson
    • 1
    • 2
  1. 1.Tufts University School of MedicineBostonUSA
  2. 2.Department of Medicine, Division of EndocrinologyTufts-New England Medical Center HospitalBostonUSA

Personalised recommendations